Leading together

Dr. Ballal has served as a member of our board of directors since August 2022. Dr. Ballal is a biopharmaceutical executive with more than 15 years of experience in business development, strategic transactions and company financing, as well as significant therapeutic area expertise in hemolytic anemias. He has served as Imara’s president and chief executive officer and a member of the board of directors since June 2018. Dr. Ballal joined Imara from Northern Biologics, where he served as chief business officer, and Versant Ventures, where he served as an entrepreneur-in-residence. Previously, Dr. Ballal was vice president of business development at Flexion Therapeutics. Prior to Flexion, he held business development and leadership positions at Novartis Venture Fund, Broad Institute of MIT and Harvard and Redmind Inc. He holds a Ph.D. in biochemistry from Georgetown University, an M.S. in bioinformatics from Johns Hopkins University and a B.S. in biology from Brown University.

Mr. Capello has served as a member of our board of directors since June 2023. He has deep operational and financial expertise in the healthcare and life science sectors. Most recently, he was the chief financial officer for Biogen, where he partnered with the executive team to achieve consistent and predictable financial outcomes while enhancing the R&D pipeline and implementing a disciplined capital allocation process. Earlier in his career, Mr. Capello served as a chief financial officer of several leading healthcare companies, including Boston Scientific, PerkinElmer, Ortho Clinical Diagnostics and Beacon Health Options. He has served as a member of the board of directors and chair of the audit committee of several early-stage, publicly held life sciences companies, including Sirtris, OvaScience and Flex Pharma. He has an MBA from the Harvard Business School and a B.S. in business administration from the University of Vermont. He was a certified public accountant and former collegiate and professional ice hockey player.

Ms. Foster has served as a member of our board of directors since December 2014. Ms. Foster has more than 25 years of experience in human resources in the pharmaceutical industry and is the former senior vice president, global human resources at Onyx Pharmaceuticals, Inc., an Amgen subsidiary. At Onyx, which was acquired by Amgen in 2013, she led all aspects of human resources for U.S. and global operations. Prior to joining Onyx, Ms. Foster was global vice president of human resources and an executive committee member at Johnson and Johnson from 2003 to 2010. Before Johnson and Johnson, Ms. Foster held several senior human resources executive positions with Pfizer Inc. supporting its pharmaceuticals businesses in Japan, Asia, Africa, Middle East and Latin America and, notably, led the integration of both the Warner-Lambert and Pharmacia mergers for these regions. Prior to that, she gained 10 years of operational experience within The Yellow Pages. She currently serves on the board of directors of Stanford Health Care, a hospital and healthcare system, and also serves on the boards of Spelman College, Glide Memorial Church and National Resilience, Inc. Ms. Foster is also very active in her community and has received several awards for her work. She earned her undergraduate degree at Baruch College of the City University of New York and received her MBA from Columbia University, Graduate School of Business.

Dr. Fouse has served as a member of our board of directors since December 2017 and as board chair since August 2022. She served as chief executive officer of Agios from February 2019 to August 2022. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. Fouse joined Celgene in 2010 as chief financial officer and was named president of the company’s global hematology & oncology franchise in 2014. Before joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, a leading global agribusiness and food company. Prior to Bunge, she served as senior vice president, chief financial officer, and head of corporate strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her tenure with Alcon, she held a variety of senior leadership roles with international companies, spending almost a decade of her career in Switzerland. Dr. Fouse also serves on the board of directors of Incyte Corporation. Dr. Fouse earned her B.A. and M.A. in economics and a Ph.D. in finance from the University of Texas at Arlington.

Brian Goff joined Agios as chief executive officer and a member of our board of directors in August 2022. He has more than 30 years of experience in the biopharmaceutical industry, and for the past 10 years has been an executive global leader focused on rare diseases. Previously, he was executive vice president, chief commercial and global operations officer of Alexion Pharmaceuticals until its acquisition by AstraZeneca in 2021. In this role, he led worldwide commercial and country operations as well as global manufacturing and product supply. Prior to joining Alexion in June 2017, Mr. Goff was chief operating officer and a member of the board of directors of Neurovance, a venture-backed company acquired by Otsuka Pharmaceuticals in 2017. Prior to joining Neurovance, Mr. Goff served as Baxalta’s executive vice president and president of the hematology division until Shire Pharmaceuticals acquired Baxalta in 2016. He previously served with Baxter Healthcare Corporation as global hemophilia franchise head. Earlier in his career, Mr. Goff held positions of increasing responsibility in sales and marketing roles in both the U.S. and in Europe with Novartis Pharmaceuticals. Mr. Goff began his career and served nearly 14 years in the pharmaceutical division of Johnson & Johnson.

Dr. Ho was appointed as an independent director to our board in June 2015. Dr. Ho has more than 30 years of experience in the healthcare and finance industries. She is a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst, co-head of healthcare for global investment research and advisory director for healthcare investment banking. Previously, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company. She is a member of the board of directors and chair of the audit committee for the Aaron Diamond AIDS Research Center in New York. She serves on the board of directors of Fibrogen, Inc. and Biomarin Pharmaceutical. She also served on the investment committee of the Society of Neuroscience. Dr. Ho was a postdoctoral fellow at the pathology department of Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. She received a Ph.D. in microbiology and immunology and a B.S. from the State University of New York, Downstate Medical Center.

Ms. Owen has served as a member of our board of directors since June 2023. She has nearly 30 years of experience in the industry and deep expertise in commercializing transformative medicines both in the U.S. and globally. In her current role as senior vice president and general manager, U.S. commercialization at Bristol Myers Squibb, Ms. Owen leads the company’s cardiovascular, immunology and oncology U.S. commercialization efforts, which contributed more than one-third of the company’s total revenue in 2022 exceeding $17 billion, and oversees a team of more than 2,500 employees. Prior to her current role, Ms. Owen was senior vice president, major markets, at Bristol Myers Squibb, responsible for the company’s business in the largest global markets including Europe, Japan and Canada. In this role, she also led multiple new product launches in multiple sclerosis, multiple myeloma, lung cancer, renal cancer and ulcerative colitis. Previously, Ms. Owen was a senior executive at Johnson & Johnson. During her more than 25 years there, she held leadership roles in pharmaceuticals, medical devices and corporate innovation in the U.K., the U.S., Europe and global organizations. In her last role, she was president, immunology, U.S. at Janssen Pharmaceuticals, leading brands such as Stelara, Remicade, Simponi and Tremfya, serving patients within the areas of dermatology, gastroenterology and rheumatology. Ms. Owen has an honors degree in pharmacy from the University of Manchester, U.K., is a member of the Royal Pharmaceutical Society of Great Britain and obtained a post-graduate diploma in marketing from the University of London. She has received numerous awards including the Medical Marketing and Media (MM+M) Hall of Femme Award in 2020 and the Healthcare Businesswomen’s Association Luminary Award in 2018.

Dr. Scadden has served as a member of our board of directors since June 2017. Dr. Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He founded and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute and is chairman and professor of the Harvard University Department of Stem Cell and Regenerative Biology. Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He has published over 300 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem cell function. Dr. Scadden is the recipient of numerous honors including membership in the National Academy of Medicine, the American Academy of Arts and Sciences and awards from the American Society of Hematology, the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Welcome Fund, and the Leukemia and Lymphoma Society. He has served or serves on the board of scientific counselors for the National Cancer Institute, the board of external experts for the National Heart, Lung and Blood Institute, board of directors of the International Society for Stem Cell Research (ISSCR), and is an associate member of the Broad Institute of Harvard and MIT. He serves on multiple editorial and scientific advisory boards, is a scientific founder of Fate Therapeutics and Magenta Therapeutics and serves on the board of directors for Magenta Therapeutics and Editas Medicine.

Dr. Schenkein joined Agios in August 2009 and served as president and chief executive officer until February 2019. He has also served as a member of our board of directors since August 2009. He served as our executive chair from February 2019 to February 2020, and as the chair of our board of directors from February 2020 to August 2022. He now serves as a general partner for life sciences at Google Ventures. He has been a hematologist and medical oncologist for more than 20 years and currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the senior vice president, clinical hematology/oncology, at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. In addition to Agios, he currently serves on the board of directors of Denali Therapeutics, Inc. Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.

Ms. Smith has served as a member of our board of directors since August 2022. Ms. Smith is a biopharmaceutical executive with 25 years of experience leading companies through complex transformations, including the transition from clinical development to commercialization and successfully launching products in a number of therapeutic areas. Most recently, she served as chief commercial officer of ZS Pharma. Previously, Ms. Smith was vice president of market access and commercial development at Affymax, where she played a key role in launching the company’s initial renal medication. Prior to joining Affymax, she held several leadership positions at Merck in market access, corporate and commercial strategy, public policy and external affairs. Before working in the biopharmaceutical industry, Ms. Smith served as a healthcare policy analyst in the White House Office of Management and Budget. Ms. Smith currently serves on the boards of Protara Therapeutics, Spero Therapeutics and Akebia Therapeutics. She holds an M.B.A. from the Wharton School of the University of Pennsylvania, an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University and a B.A. from the University of North Carolina at Chapel Hill.

Dr. Cantley is a foremost expert in understanding the biochemical pathways linking cancer and energy metabolism. His key contributions include:

• Discovering the phosphatidylinositol-3-kinase (PI3K) signaling pathway
• Characterizing the mechanism by which PI3K is activated by growth factors and oncogenes and elucidating pathways downstream of PI3K, including the AKT/PKB signaling pathway
• Pioneering the application of fluorescence resonance energy transfer (FRET) for studying small molecule cell membrane transport
• Discovering pyruvate kinase M2 (PKM2) as a “hub” to integrate growth factor signaling and aerobic glycolysis, an evolution in the understanding of the Warburg effect.

Dr. Mak is a preeminent researcher of the biology of the immune system, the biology of apoptosis and the pathogenesis of cancer. His key contributions include:

• Discovering the T-Cell receptor
• Characterizing the tumorigenic functions of the tumor suppressor protein p53 and the kinase Chk2
• Identifying CPT1C as a tumor-specific gene product that plays an important role in the utilization of fatty acids as an alternative energy source of cancer cells
• Discovery of the function of CTLA-4

Dr. Su was one of Agios’ founding scientists and its first employee. He served as senior vice president, research & development from 2012-2016. Dr. Su has more than 20 years of organization, project management and scientific experience in the biotechnology industry. Prior to Agios, from 2004 to 2006, he served as general director and vice president of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior to that, he spent 14 years in a number of roles, concluding his tenure as program executive and vice president of the Novartis kinase collaboration for Vertex Pharmaceuticals, a publicly traded pharmaceutical company. Dr. Su earned his Ph.D. in biochemistry at Duke University and was a Helen Hay Whitney Fellow at Harvard University.

Dr. Thompson is an authority in the study of how genes regulate apoptosis and metabolism and investigates their application in treating cancer. His key contributions include:

• Elucidating the role of the Bcl-2 family of oncogenes role in regulating cell survival
• Identifying the roles of aerobic glycolysis, fatty acid synthesis and autophagy in the metabolic adaptation by cancer cells as part of carcinogenesis
• Proposing the concept that most oncogenes and tumor suppressors evolved to regulate cellular metabolism